Literature DB >> 28096939

Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?

Georg A Bjarnason1.   

Abstract

The recommended starting dose and schedule for sunitinib is 50 mg daily for 28 days, followed by a 14-day break with significant dose reductions to 37.5 mg (75% of starting dose), and then 25 mg (50% of starting dose) on the same schedule (four/two schedule). There are several reasons why these dose and scheduling recommendations may not be optimal for most patients, as outlined below.

Entities:  

Year:  2016        PMID： 28096939      PMCID： PMC5215304          DOI： 10.5489/cuaj.4293

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


  29 in total

1.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Authors:  Dirk Strumberg; Heike Richly; Ralf A Hilger; Norbert Schleucher; Sonke Korfee; Mitra Tewes; Markus Faghih; Erich Brendel; Dimitris Voliotis; Claus G Haase; Brian Schwartz; Ahmad Awada; Rudolf Voigtmann; Max E Scheulen; Siegfried Seeber
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

2.  Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.

Authors:  Andrea Mancuso; Eugenio Donato Di Paola; Alvaro Leone; Alfonso Catalano; Fabio Calabrò; Linda Cerbone; Andrea Zivi; Carlo Messina; Silvia Alonso; Leonardo Vigna; Rita Caristo; Cora N Sternberg
Journal:  BJU Int       Date:  2012-01       Impact factor: 5.588

3.  Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma.

Authors:  Xiuwu Pan; Hai Huang; Yi Huang; Bing Liu; Xingang Cui; Sishun Gan; Jianqing Ye; Danfeng Xu; Lu Chen; Qiwei Zhou; Lin Li; Yi Hong
Journal:  Urol Oncol       Date:  2015-04-08       Impact factor: 3.498

4.  A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.

Authors:  Robert Amato; Jim Zhai; James Willis; Somyata Saxena; Melissa DeFoe
Journal:  Clin Genitourin Cancer       Date:  2012-05-01       Impact factor: 2.872

5.  Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.

Authors:  Remi Adelaiye; Eric Ciamporcero; Kiersten Marie Miles; Paula Sotomayor; Jonathan Bard; Maria Tsompana; Dylan Conroy; Li Shen; Swathi Ramakrishnan; Sheng-Yu Ku; Ashley Orillion; Joshua Prey; Gerald Fetterly; Michael Buck; Sreenivasulu Chintala; Georg A Bjarnason; Roberto Pili
Journal:  Mol Cancer Ther       Date:  2014-12-17       Impact factor: 6.261

6.  Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.

Authors:  Pascaline Boudou-Rouquette; Stanislas Ropert; Olivier Mir; Romain Coriat; Bertrand Billemont; Michel Tod; Laure Cabanes; Nathalie Franck; Benoit Blanchet; François Goldwasser
Journal:  Oncologist       Date:  2012-07-02

7.  Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.

Authors:  Georg A Bjarnason; Bishoy Khalil; John M Hudson; Ross Williams; Laurent M Milot; Mostafa Atri; Alex Kiss; Peter N Burns
Journal:  Urol Oncol       Date:  2013-12-08       Impact factor: 3.498

Review 8.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Authors:  Brett E Houk; Carlo L Bello; Bill Poland; Lee S Rosen; George D Demetri; Robert J Motzer
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-05       Impact factor: 3.333

9.  Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

Authors:  Bernard Escudier; Jan Roigas; Silke Gillessen; Ulrika Harmenberg; Sandhya Srinivas; Sasja F Mulder; George Fountzilas; Christian Peschel; Per Flodgren; Edna Chow Maneval; Isan Chen; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

10.  Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients.

Authors:  Bruno Neri; Agnese Vannini; Marco Brugia; Andrea Muto; Sheila Rangan; Mattia Rediti; Renato Tassi; Carmine Cerullo
Journal:  Int J Urol       Date:  2012-11-01       Impact factor: 3.369
View more
  3 in total

1.  Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

Authors:  Sebastien J Hotte; Anil Kapoor; Naveen S Basappa; Georg Bjarnason; Christina Canil; Henry J Conter; Piotr Czaykowski; Jeffrey Graham; Samantha Gray; Daniel Y C Heng; Pierre I Karakiewicz; Christian Kollmannsberger; Aly-Khan A Lalani; Scott A North; François Patenaude; Denis Soulières; Phillippe Violette; Eric Winquist; Lori A Wood; Shaan Dudani; Ranjena Maloni; M Neil Reaume
Journal:  Can Urol Assoc J       Date:  2019-10       Impact factor: 1.862

Review 2.  Evaluation of and Current Trends in the Management of Gastrointestinal Stromal Tumors: A Systematic Review.

Authors:  Hadia Arzoun; Mirra Srinivasan; Mona Adam; Siji S Thomas; Amber Kuta; Stephanie Sandoval
Journal:  Cureus       Date:  2022-07-14

3.  Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

Authors:  M Neil Reaume; Naveen S Basappa; Lori Wood; Anil Kapoor; Georg A Bjarnason; Normand Blais; Rodney H Breau; Christina Canil; Patrick Cheung; Henry J Conter; Sebastien J Hotte; Claudio Jeldres; Michael A S Jewett; Pierre I Karakiewicz; Christian Kollmannsberger; Francois Patenaude; Alan So; Denis Soulières; Peter Venner; Phillippe Violette; Pawel Zalewski; Heather Chappell; Scott A North
Journal:  Can Urol Assoc J       Date:  2017-10       Impact factor: 1.862
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.